Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide and Relugolix in High-Risk Prostate Cancer
NCT06631521Phase 1Recruiting
- Sponsor
- AdventHealth
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of darolutamide and tissue-plasminogen activator in prostate cancer (PCa), sponsored by AdventHealth. Primary endpoints: Percentage of patients completing therapy without severe adverse events and Number of patients experiencing treatment-related adverse events. Started Oct 2024; status: recruiting.
02
Drugs
darolutamidetissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06631521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631521.